Anacor Pharmaceuticals

Anacor Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases.
Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.

Type
Subsidiary
Parent Company
Pfizer
HQ
Palo Alto, US
Founded
2002
Website
anacor.com
Anacor Pharmaceuticals was founded in 2002 and is headquartered in Palo Alto, US

Anacor Pharmaceuticals Office Locations

Anacor Pharmaceuticals has an office in Palo Alto
Palo Alto, US (HQ)
1020 E Meadow Cir

Anacor Pharmaceuticals Financials and Metrics

Anacor Pharmaceuticals Summary

In total, Anacor Pharmaceuticals had raised $198.4 m. Anacor Pharmaceuticals is a subsidiary of Pfizer

Anacor Pharmaceuticals Financials

Anacor Pharmaceuticals's revenue was reported to be $82.4 m in FY, 2015
USDFY, 2013FY, 2014FY, 2015

Revenue

17.2 m20.7 m82.4 m

Revenue growth, %

20%298%

Cost of goods sold

797 k4 m

Gross profit

17.2 m19.9 m78.3 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016

Revenue

4.2 m2.9 m4 m15.3 m21.3 m24.6 m17.5 m

Cost of goods sold

202 k754 k680 k591 k929 k

Gross profit

3.8 m14.5 m20.7 m24 m16.6 m

Gross profit Margin, %

95%95%97%98%95%
USDFY, 2013FY, 2014FY, 2015

Cash

114.8 m16 m53.7 m

Inventories

2.3 m4.3 m6.5 m

Current Assets

155.4 m160.3 m170.1 m

PP&E

1.5 m1.6 m2.3 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016

Cash

14.8 m20 m16.9 m22.1 m7.5 m10.2 m25 m

Inventories

1.4 m2.3 m3.2 m3.5 m2.7 m

Current Assets

139.9 m131.3 m149.6 m186.3 m181.8 m180.8 m157.3 m

PP&E

1.5 m1.6 m1.7 m1.6 m1.7 m1.7 m2.3 m
USDFY, 2013FY, 2014FY, 2015

Net Income

84.8 m(87.1 m)(61.2 m)

Depreciation and Amortization

507 k499 k629 k

Inventories

(2.4 m)(2.2 m)

Accounts Payable

1.7 m(188 k)758 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015

Net Income

(21.2 m)(24.5 m)(31.3 m)(13 m)

Accounts Payable

5.1 m
Show all financial metrics

Anacor Pharmaceuticals Operating Metrics

FY, 2015

Patents Issued

6
Show all operating metrics

Anacor Pharmaceuticals's Web-traffic and Trends

Anacor Pharmaceuticals Company Life and Culture

You may also be interested in